Jane Chung - 04 Mar 2022 Form 4 Insider Report for SUTRO BIOPHARMA, INC. (STRO)

Role
Chief Commercial Officer
Signature
/s/ Edward C. Albini as attorney-in-fact for Jane Chung
Issuer symbol
STRO
Transactions as of
04 Mar 2022
Net transactions value
$0
Form type
4
Filing time
07 Mar 2022, 18:33:04 UTC
Previous filing
11 Aug 2021
Next filing
10 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STRO Stock Option (right to buy) Award $0 +42,000 $0.000000 42,000 04 Mar 2022 Common Stock 42,000 $8.17 Direct F1
transaction STRO Restricted Stock Unit (RSU) Award $0 +31,500 $0.000000 31,500 04 Mar 2022 Common Stock 31,500 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to 2.0833% of the total shares monthly, beginning on April 4, 2022, with 100% of the total shares vested and exercisable on March 4, 2026, subject to the reporting person's provision of service to the issuer on each vesting date.
F2 Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.
F3 The RSUs vest as to 1/4th of the total shares annually beginning on March 4, 2023, subject to continued service through each vesting date.